Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You've just pointed out the point I've been trying to make. Doctors have trusted sources, they trust you. They trust certain sources for medical information. Once Vascepa gets there it will take off. My mom was in real estate and had neurosurgeon in Los Gatos that used her for all the house transfers as he divorced several times over long period.
ah but they will, people will have their stomachs stapled and their esophaguses banded, take toxic diet and lipid meds to get out of dieting and exercising. If Vascepa works and it's side effect free, they will pay.
Yes you did sorry, I read article you were responding to and just scanned yours
The PDUFA will not be a nonevent. A while back a cardiologist wrote the FDA will deny ANCHOR and it was widely publicized by Adam Feuerstein and his cohorts. The cardiologist said he was misquoted and others disputed him but the stock took a hit and is now only starting to recover.
So AK, how do you think we should figure all this out. My ancestry is Hungarian so I'd probably like more Eastern Europeans in the study. Where I live is mostly Asian and they eat a lot of fish even though they're Americans. Does your cardiologist know enough about statistics to figure out the significance of all the data coming in?
Plaque is my first favorite thing about Vascepa, my triglycerides are normal, I take it so I don't have to brush my teeth any more.
Yeah but that's Danish, not Americans, they eat Danish pastry, Kaiser recommends you ignore this study until redone on Americans, that homogeneous population more like us.
How many studies are more than 50% "Americans?" There's a lot of good studies coming out of other countries also. And in the US there's always race specific effects of drugs, often additional studies are required to dig this out.
That's not a reasonable position to take
I'm sure you could pull up the same data on heart catheterizations that are done very frequently
Right, there's a lot of silent MIs, diabetics have nerve pathology and often the pain doesn't transmit. False negative, but the converse false positive from angina doesn't exist. What your cardiologist is talking about hard data is that investigators might mistake angina for other types of chest pain. If you can test better and prove Vascepa is actually preventing angina, we're rich and the shorts are bankrupt.
I agree with most of what you said except the "just angina" discounting. Angina is not just an annoying symptom. It is usually ischemia and a harbinger to an MI. There is a lot of research, new medications, and surgery dedicated to decreasing the causes of angina. A med with no side effects that decreases angina will have as much of an upside as a downside exists by shorting AMRN.
Shorting AMRN with infinite risk is the only way to get absolutely crushed, e.g., last few days of AMRN green, hog crushed
Red rice yeast is more natural than fish oil? Red rice yeast contains the same chemicals as statins and includes the same risks, e.g., it can wreck your liver, muscles, and kidneys
I can tell you my LDL-C decreased 10% on 90 days' 4g Vascepa without statins, on a worse diet and less exercise.
I think your projected numbers are way off. Anchor and Marine populations are based on real patient populations not Lovaza sales. All meds are sold off label once approved for market. Vascepa off label sales will dwarf Lovaza's as less negative side effects and more positive side effects.
You're probably right about that
Na we're waitin' for the big money, rest of the market red, glad I didn't wake up in a short position.
Go to clinicaltrials.gov, you have to be on a stable dose of statin to qualify for Anchor.
As long as you don't identify the patient HIPPA is ok
Not expanded, patients high risk for CHD always there, doesn't say treat, says for patients with
That's what I thought you meant but still qualifies for the oxymoron award, maybe not the serious part
More cheap advertising not involving reps. Just got very impressive email offer for Qsymia and I'm not even fat. Amarin needs some of this.
DS cardiologist work at Kaiser?
You can take a sample then come up with a statistically significant small error estimate
Not true, inclusion criteria was stable dose of statin
Are they weak or just treating a smaller population.
Yes and once ANCHOR is approved almost all Lovaza's will be off label in contrast to Vascepa. That combined with Lovaza's LDL problem will require all physicians,insurance companies, text books, protocols to require Vascepa. Might be a lot of Lovaza reps but nothing they can say, just supply free lunch.
AMRN 20,000 calls 3,300 puts as of 1230 ET, higher than normal volume
Dang shoulda shorted something else, snake oil crap only thing green last few days, oh well start over, after deal with broker calling for cover, pig slaughtered!
I'm not debating the CHD or if equivalents increases it. I'm saying label will not be for treating CHD or its equivalents. Vascepa will treat lab lipid values only. The restriction is that the patients must have both CHD (or equivalents) and lipid abnormalities to be on label, but it's not treating CHD,if that occurs fine, but wait for reduce-it for that label
I don't agree, sounds like more of a restriction. Vascepa will be used to treat lab values only, but can only be used if patient has CHD and lipid abnormalities.
ANCHOR patients had to be high risk for CHD, but Vascepa not yet studied to decrease CHD
None of that is true here
And if you short AMRN, i.e., borrowing shares from a broker, the risk is infinite.
How do we get free publicity like some of the other drug companies? Yesterday in the SF Chronicle Health section front page section large promoting first new weight loss drug. Should we write to newspaper editors?
Wrong, selling naked call options carries infinite risk
Look up shorting, say "infinite risk." you can always look back and say no risk, made a few dollars, but one green day and you're sorry.
The most successful short on AMRN that has posted made a total of $36k, was at unlimited risk every day, spent more time on the the stock than could have made by being employed, and recently bought AMRN and closed out short position.
You're just making stuff up. Your previous posts say you didn't own in July and were considering buying after July 24. AMRN hasn't been $7 since end of May early June.
So you bought AMRN last month when it peaked above $7, I bought a lot at $5, sorry it's hard to buy low sell high.